Patient characteristics and treatment results from selected clinical trials enrolling children with ALL
| Study group . | Years of study . | No. of patients . | Age, y, range . | T-cell ALL, % . | 5-y outcome, % . | Data source . | ||
|---|---|---|---|---|---|---|---|---|
| Cumulative CNS relapse rate . | EFS . | Survival . | ||||||
| AIEOP-95 | 1995-2000 | 1743 | 0-18 | 11 | 1.2 ± 0.3 | 75.9 ± 1.0 | 85.5 ± 0.8 | Conter et al1 |
| BFM-95 | 1995-1999 | 2169 | 0-18 | 13 | 4.0 ± 0.4 | 79.6 ± 0.9 | 87.0 ± 0.7 | Möricke et al2 |
| COG | 2000-2005 | 7153 | 0-21 | 7 | NA | NA | 90.4 ± 0.5 | Hunger et al3 |
| DCOG-9 | 1997-2004 | 859 | 1-18 | 11 | 2.6 ± 0.6 | 80.6 ± 1.4 | 86.4 ± 1.2 | Veerman et al4 |
| DFCI 00-01 | 2000-2004 | 492 | 1-18 | 11 | NA | 80.0 ± 2 | 91 ± 1 | Vrooman et al5 |
| NOPHO-2000 | 2002-2007 | 1023 | 1-15 | 11 | 2.7 ± 0.6 | 79.4 ± 1.5 | 89.1 ± 11 | Schmiegelow et al6 |
| SJCRH 15 | 2000-2007 | 498 | 1-18 | 15 | 2.7 ± 0.8 | 85.6 ± 2.9 | 93.5 ± 1.9 | Pui et al7 |
| UKALL 97/99 | 1999-2002 | 938 | 1-18 | 11 | 3.0 ± 0.6 | 80.0 ± 1.3 | 88.0 ± 1.1 | Mitchell et al8 |
| Study group . | Years of study . | No. of patients . | Age, y, range . | T-cell ALL, % . | 5-y outcome, % . | Data source . | ||
|---|---|---|---|---|---|---|---|---|
| Cumulative CNS relapse rate . | EFS . | Survival . | ||||||
| AIEOP-95 | 1995-2000 | 1743 | 0-18 | 11 | 1.2 ± 0.3 | 75.9 ± 1.0 | 85.5 ± 0.8 | Conter et al1 |
| BFM-95 | 1995-1999 | 2169 | 0-18 | 13 | 4.0 ± 0.4 | 79.6 ± 0.9 | 87.0 ± 0.7 | Möricke et al2 |
| COG | 2000-2005 | 7153 | 0-21 | 7 | NA | NA | 90.4 ± 0.5 | Hunger et al3 |
| DCOG-9 | 1997-2004 | 859 | 1-18 | 11 | 2.6 ± 0.6 | 80.6 ± 1.4 | 86.4 ± 1.2 | Veerman et al4 |
| DFCI 00-01 | 2000-2004 | 492 | 1-18 | 11 | NA | 80.0 ± 2 | 91 ± 1 | Vrooman et al5 |
| NOPHO-2000 | 2002-2007 | 1023 | 1-15 | 11 | 2.7 ± 0.6 | 79.4 ± 1.5 | 89.1 ± 11 | Schmiegelow et al6 |
| SJCRH 15 | 2000-2007 | 498 | 1-18 | 15 | 2.7 ± 0.8 | 85.6 ± 2.9 | 93.5 ± 1.9 | Pui et al7 |
| UKALL 97/99 | 1999-2002 | 938 | 1-18 | 11 | 3.0 ± 0.6 | 80.0 ± 1.3 | 88.0 ± 1.1 | Mitchell et al8 |
EFS indicates event-free survival; AIEOP, Associazione Italiana di Ematologia ed Oncologia Pediatrica; BFM, Berlin-Frankfurt-Münster; NA, not available; DCOG, Dutch Childhood Oncology Group; DFCI, Dana-Farber Cancer Institute consortium; NOPHO, Nordic Society of Pediatric Hematology and Oncology; SJCRH, St Jude Children's Research Hospital; and UKALL, United Kingdom Medical Research Council Working Party on Childhood Leukaemia.